C07K 16/28
Against receptors, cell surface antigens or cell surface determinants
Official title: against receptors, cell surface antigens or cell surface determinants
C07K16/28 (Against receptors, cell surface antigens or cell surface determinants) appears on 24,500 US grants and 47,466 published applications in this corpus.
Search patents in C07K- Granted patents
- 24,500
- Published applications
- 47,466
- Assignees
- 8,299
- Inventors
- 55,299
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 3 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 15 | 0 |
| 1983 | 5 | 0 |
| 1984 | 13 | 0 |
| 1985 | 12 | 0 |
| 1986 | 15 | 0 |
| 1987 | 47 | 0 |
| 1988 | 37 | 0 |
| 1989 | 71 | 0 |
| 1990 | 63 | 0 |
| 1991 | 53 | 0 |
| 1992 | 75 | 0 |
| 1993 | 106 | 0 |
| 1994 | 81 | 0 |
| 1995 | 93 | 0 |
| 1996 | 159 | 0 |
| 1997 | 256 | 0 |
| 1998 | 360 | 0 |
| 1999 | 311 | 0 |
| 2000 | 260 | 0 |
| 2001 | 273 | 90 |
| 2002 | 255 | 528 |
| 2003 | 213 | 1465 |
| 2004 | 200 | 723 |
| 2005 | 190 | 902 |
| 2006 | 329 | 884 |
| 2007 | 391 | 895 |
| 2008 | 460 | 870 |
| 2009 | 472 | 1168 |
| 2010 | 556 | 1184 |
| 2011 | 594 | 1227 |
| 2012 | 658 | 1150 |
| 2013 | 744 | 1296 |
| 2014 | 790 | 1563 |
| 2015 | 899 | 1546 |
| 2016 | 982 | 1899 |
| 2017 | 1075 | 2047 |
| 2018 | 1106 | 2308 |
| 2019 | 1336 | 2761 |
| 2020 | 1524 | 3006 |
| 2021 | 1596 | 3390 |
| 2022 | 1587 | 3479 |
| 2023 | 1514 | 3399 |
| 2024 | 1759 | 3822 |
| 2025 | 1746 | 3296 |
| 2026 | 1214 | 2568 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 16/2803Against the immunoglobulin superfamily9,337
- C07K 16/30From tumour cells7,312
- C07K 16/2863Against receptors for growth factors, growth regulators3,023
- C07K 16/2896Against molecules with a "cd"-designation, not provided for elsewhere2,467
- C07K 16/2866Against receptors for cytokines, lymphokines, interferons2,456
- C07K 16/2878Against the ngf-receptor/tnf-receptor superfamily1,952
- C07K 16/2887Against cd201,515
- C07K 16/2875Against the ngf/tnf superfamily821
All 18 subgroupsShow fewer
- C07K 16/2839Against the integrin superfamily815
- C07K 16/2851Against the lectin superfamily722
- C07K 16/2869Against hormone receptors536
- C07K 16/2881Against cd71281
- C07K 16/2893Against cd52173
- C07K 16/286Against neuromediator receptors130
- C07K 16/289Against cd4598
- C07K 16/2884Against cd4480
- C07K 16/2872Against prion molecules37
- C07K 16/2857Against nuclear receptors36
Recent patents
- Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors6 Oct 2026US 12,751,956 B2Hoffmann-La Roche Inc.
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Compositions and methods for treating cancer by targeting bach18 Oct 2026US 2026/0306455 A1
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Methods for treating or preventing asthma by administering an il-4r antagonist8 Oct 2026US 2026/0306627 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Recombinant immunoglobin preparations4,785US 4,816,567 AGenentech, Inc. · 1989
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Single polypeptide chain binding molecules2,454US 4,946,778 AGenex Corporation · 1990
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997